Wednesday, May 18, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

by Medical Finance
in Coronavirus
Study: Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Persistent hard work and groundbreaking research by scientists have led to the development of several vaccines to limit the spread of severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19) pandemic. However, the frequency of ‘breakthrough’ infections in fully vaccinated individuals increased with the appearance of the Delta variant of concern (VOC).


Study: Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals. Image Credit: PHOTOCREO Michal Bednarek/ShutterstockStudy: Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock


This suggests that novel SARS-CoV-2 variants may mediate the degree of escape from immunity within vaccinated individuals. However, it is unclear whether such infections led to onward transmission. A new study, published on the medRxiv* preprint server, assessed the levels of infectious virus (obtained from the nasopharynx) in vaccinated and unvaccinated individuals.


Motivation


Previous research showed that breakthrough infections with the Delta VOC generated similar levels of viral nucleic acids among vaccinated and unvaccinated individuals. However, controlling for similar Ct values, is there a significant difference between the infectivity of vaccinated and unvaccinated individuals? Further, the duration of protection provided by vaccination in vaccinated individuals infected with SARS-CoV-2 variants remains unknown.


A new study


Researchers conducted a study involving 125 (72 vaccinated and 53 unvaccinated) patients to address the questions above. Nasopharyngeal samples were obtained from excess clinical samples used to diagnose SARS-CoV-2 infection. The study period was July to August 2021, during which the Delta VOC was the predominant circulating variant.


To allow for significant heterogeneity, nasopharyngeal samples were selected from a range of RT-qPCR cycle threshold (Ct) values among vaccinated individuals. These were, subsequently, matched with corresponding Ct values among unvaccinated individuals. Further, within given Ct ranges, individuals were matched by other characteristics, such as age and sex, to control for demographic differences between cohorts. After matching vaccinated and unvaccinated cohorts, scientists observed no significant differences in age or sex. 41.6% were male, and the mean age was 46.9 years. 


Sixty-five individuals with breakthrough infections had completed a standard two-dose mRNA vaccination program among the vaccinated cohort. Seven vaccinated individuals received a single dose of a SARS-CoV-2 adenovirus vector vaccine (Johnson and Johnson).


Main findings


Scientists found no significant difference in SARS-CoV-2 genome copy numbers between vaccinated and unvaccinated infections, controlling for differences in clinical testing platforms. Subsequently, they performed quantitative plaque assays to study whether there were differences in levels of infectious virus between breakthrough infections and unvaccinated individuals. Once again, no significant differences were found across cohorts.


The next step was to analyze the proportion of nasopharyngeal samples with a culturable virus. Researchers observed a lower percentage of infectious samples in vaccinated patients (21%) relative to unvaccinated patients (40%). Taken together, these data suggest that the current vaccines may not change the levels of replicating virus in the upper respiratory tract once viral infection establishes. However, the vaccines may protect enhanced neutralization of infectious viral particles or rapid clearance.


It is important to understand if the probability of culturing infectious viruses is mainly driven by demographic factors or differences in disease trajectories. To address this issue, scientists used a log-binomial model with robust standard errors to predict the probability of detecting infectious viruses among vaccinated and unvaccinated patients.


It was observed that vaccination significantly reduced the presence of infectious virus during breakthrough infection (by 51%). Among patients that completed two doses of the mRNA vaccine, it was observed that this protection waned significantly with time, starting at five months post-vaccination. Overall, the data suggested a marked loss in protection against the presence of infectious viruses among vaccinated individuals.


Conclusion


These results obtained in the current study are in line with previous studies that suggested that mRNA vaccination protection decreases over time. These results have important implications concerning the timing of booster jabs to prevent onward transmission from breakthrough cases. Scientists stated that the adoption of mRNA boosters in a critical 4–6-month window could reduce the transmissibility of the virus among fully vaccinated individuals with breakthrough infections.


*Important notice


medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study finds poorer outcomes after ICU discharge in patients with alcohol-associated cirrhosis

Study finds poorer outcomes after ICU discharge in patients with alcohol-associated cirrhosis

by Medical Finance
May 18, 2022
0

Patients with alcohol-associated cirrhosis have poorer outcomes after ICU discharge, compared to patients with cirrhosis linked to other causes, according...

Study: Association of SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality From Obstetric Complications. Image Credit: milkumistock / Shutterstock.com

The serious risks COVID-19 may pose during pregnancy

by Medical Finance
May 18, 2022
0

In a recent JAMA study, researchers report on the potential for serious maternal illness or death during or following a pregnancy...

Study: BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine. Image Credit: Tamer Adel Soliman/Shutterstock

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

by Medical Finance
May 18, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic has severely disrupted the world in terms of the disease burden and...

Study: Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Image Credit: Kateryna Kon / Shutterstock.com

How SARS-CoV-2 infection progresses throughout the respiratory system

by Medical Finance
May 18, 2022
0

In a recent Thorax state of the art review, researchers discuss the progression of the severe acute respiratory syndrome coronavirus...

Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

by Medical Finance
May 18, 2022
0

The rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has resulted in the coronavirus disease...

Study: Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection. Image Credit: Marina Demidiuk / Shutterstock.com

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

by Medical Finance
May 18, 2022
0

In most developed countries, several vaccines have been developed against the coronavirus disease 2019 (COVID-19), all of which target the...

Next Post
What are the benefits of Irish Life Sciences’ new 2.2 mL square well ‘V’ bottom plate?

What are the benefits of Irish Life Sciences' new 2.2 mL square well 'V' bottom plate?

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • 163926142 620x480
    New findings could contribute to future therapeutics for muscle degeneration
  • shutterstock 1155822118 1
    Developing Biochemically Sensitive Membranes with Electrochemistry
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply